Who
Paul F. Lizzul
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, First Tracks Biotherapeutics; Chief Medical Officer, AnaptysBio; Chief Medical Officer, Sienna Biopharmaceuticals.
In numbers
- Trades disclosed
- 115
- Buys
- 1
- Sells
- 10
- Bought
- $150K
- Sold
- $1.3M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 26 Jul 2017
- Last trade
- 15 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Aug 2026filed 18 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,492 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,492 at $0.00 | filing |
| 2 Aug 2026filed 5 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,492 at $0.00 | filing |
| 2 Aug 2026filed 5 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,492 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,300 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,300 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,500 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,575 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,400 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,500 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,070 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,540 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,200 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.